All In Biotech

Drug Trial Radar · NCT01704859

VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 25,871 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25,871

Actual

Start

Jun 1, 2018

Primary completion

Mar 31, 2022

Study completion Nov 23, 2022

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted
Oct 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine (1) whether vitamin D reduces incident total, non-vertebral fractures, and hip fractures and (2) whether this reduction is modified by vitamin D levels

Conditions

  • Fractures

Interventions

  • Vitamin D3 placeboDietary supplement

    Vitamin D placebo

  • Fish oil placeboDietary supplement

    Fish oil placebo

  • omega-3 fatty acids (fish oil)Drug

    Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

  • Vitamin D3Dietary supplement

    Vitamin D3 (cholecalciferol), 2000 IU per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident total, non-vertebral, and hip fracturesTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.